CDK4/6 Inhibitors: Game Changers in the Management of Hormone ReceptorPositive Advanced Breast Cancer?
Oncology (Williston Park)
; 32(5): 216-22, 2018 05 15.
Article
en En
| MEDLINE
| ID: mdl-29847850
ABSTRACT
The cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors palbociclib, ribociclib, and abemaciclib are rapidly transforming the care of patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (HR+/HER2-) advanced breast cancer. Current clinical questions include how to choose among these agents and how to sequence them with other therapies. Areas of active inquiry include identifying predictive biomarkers for CDK4/6 inhibitors, deciding whether to continue CDK4/6 inhibitors after disease progression, creating novel treatment combinations, and expanding use beyond HR+/HER2- advanced breast cancer. Here, we review the current use of and potential next directions for CDK4/6 inhibitors in the treatment of patients with HR+ breast cancer.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Neoplasias de la Mama
/
Receptores de Progesterona
/
Receptores de Estrógenos
/
Receptor ErbB-2
/
Inhibidores de Proteínas Quinasas
/
Quinasa 4 Dependiente de la Ciclina
/
Quinasa 6 Dependiente de la Ciclina
/
Antineoplásicos
Tipo de estudio:
Prognostic_studies
Límite:
Female
/
Humans
Idioma:
En
Revista:
Oncology (Williston Park)
Asunto de la revista:
NEOPLASIAS
Año:
2018
Tipo del documento:
Article